The fourth, Reduction of Peritoneal Glucose Uptake with Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE) [NCT05250752], is a cross-sectional study that will include 10 patients on PD who will receive dapagliflozin at 10 mg per day. This evidence concerns the gene SLC5A2 and kidney failure.